Transcriptome Analysis Reveals Key Genes and Pathways Associated with Metastasis in Breast Cancer

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Kodack DP, Askoxylakis V, Ferraro GB, et al. Emerging strategies for treating brain metastases from breast cancer. Cancer Cell. 2015;27(2):163–175. doi:10.1016/j.ccell.2015.01.00125670078
   PubMed Web of Science ®Google Scholar
• Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271–3277. doi:10.1200/JCO.2009.25.982020498394
   PubMed Web of Science ®Google Scholar
• Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3(6):537–549. doi:10.1016/S1535-6108(03)00132-612842083
   PubMed Web of Science ®Google Scholar
• Dittmer J. Mechanisms governing metastatic dormancy in breast cancer. Semin Cancer Biol. 2017;44:72–82. doi:10.1016/j.semcancer.2017.03.00628344165
   PubMed Web of Science ®Google Scholar
• Pradhan S, Slater JH. Tunable hydrogels for controlling phenotypic cancer cell states to model breast cancer dormancy and reactivation. Biomaterials. 2019;215:119177. doi:10.1016/j.biomaterials.2019.04.02231176804
   PubMed Web of Science ®Google Scholar
• Untch M, von Minckwitz G, Gerber B, et al. Survival analysis after neoadjuvant chemotherapy with trastuzumab or lapatinib in patients with human epidermal growth factor receptor 2-positive breast cancer in the GeparQuinto (G5) study (GBG 44). J Clin Oncol. 2018;36(13):1308–1316. doi:10.1200/JCO.2017.75.917529543566
   PubMed Web of Science ®Google Scholar
• Earl HM, Hiller L, Vallier AL, et al. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised Phase 3 non-inferiority trial. Lancet. 2019;393(10191):2599–2612. doi:10.1016/S0140-6736(19)30650-631178152
   PubMed Web of Science ®Google Scholar
• Esteva FJ, Hubbard-Lucey VM, Tang J, et al. Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncol. 2019;20(3):e175–e186. doi:10.1016/S1470-2045(19)30026-930842061
   PubMed Web of Science ®Google Scholar
• Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486(7403):400–404. doi:10.1038/nature1101722722201
   PubMed Web of Science ®Google Scholar
• Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439–1445. doi:10.1038/ng.282224185512
   PubMed Web of Science ®Google Scholar
• Kimbung S, Kovacs A, Bendahl PO, et al. Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences. Mol Oncol. 2014;8(1):119–128. doi:10.1016/j.molonc.2013.10.00224287398
   PubMed Web of Science ®Google Scholar
• Lu X, Gao C, Liu C. et al. Identification of the key pathways and genes involved in HER2-positive breast cancer with brain metastasis. Pathol Res Pract;2019 152475. doi:10.1016/j.prp.2019.15247531178227
   PubMed Web of Science ®Google Scholar
• Zhao XG, Hu JY, Tang J, et al. miR-665 expression predicts poor survival and promotes tumor metastasis by targeting NR4A3 in breast cancer. Cell Death Dis. 2019;10(7):479. doi:10.1038/s41419-019-1705-z31209222
   PubMedGoogle Scholar
• Wright GW, Simon RM. A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics. 2003;19(18):2448–2455. doi:10.1093/bioinformatics/btg34514668230
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307. doi:10.1038/nature1014421593862
   PubMed Web of Science ®Google Scholar
• Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432(7015):332–337. doi:10.1038/nature0309615549095
   PubMed Web of Science ®Google Scholar
• Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–563. doi:10.1038/nature0618817914389
   PubMed Web of Science ®Google Scholar
• Erez N, Coussens LM. Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization. Int J Cancer. 2011;128(11):2536–2544. doi:10.1002/ijc.v128.1121387299
   PubMed Web of Science ®Google Scholar
• Brodt P. Role of the microenvironment in liver metastasis: from pre- to prometastatic niches. Clin Cancer Res. 2016;22(24):5971–5982. doi:10.1158/1078-0432.CCR-16-046027797969
   PubMed Web of Science ®Google Scholar
• Aguirre-Ghiso JA, Liu D, Mignatti A, et al. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell. 2001;12(4):863–879. doi:10.1091/mbc.12.4.86311294892
   PubMed Web of Science ®Google Scholar
• Aguirre Ghiso JA, Kovalski K, Ossowski L. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling. J Cell Biol. 1999;147(1):89–104. doi:10.1083/jcb.147.1.8910508858
   PubMed Web of Science ®Google Scholar
• Harper KL, Sosa MS, Entenberg D, et al. Corrigendum: mechanism of early dissemination and metastasis in Her2(+) mammary cancer. Nature. 2018;553(7688):366. doi:10.1038/nature24666
   PubMed Web of Science ®Google Scholar
• Seraj MJ, Samant RS, Verderame MF, et al. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res. 2000;60(11):2764–2769.10850410
   PubMed Web of Science ®Google Scholar
• Hedley BD, Vaidya KS, Phadke P, et al. BRMS1 suppresses breast cancer metastasis in multiple experimental models of metastasis by reducing solitary cell survival and inhibiting growth initiation. Clin Exp Metastasis. 2008;25(7):727–740. doi:10.1007/s10585-008-9184-018543067
   PubMed Web of Science ®Google Scholar
• Xu C, Zhao H, Chen H, et al. CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Des Devel Ther. 2015;9:4953–4964. doi:10.2147/DDDT.S84932
   PubMed Web of Science ®Google Scholar
• Vesuna F, Bergman Y, Raman V. Genomic pathways modulated by twist in breast cancer. BMC Cancer. 2017;17(1):52. doi:10.1186/s12885-016-3033-328086829
   PubMedGoogle Scholar
• Sadanandam A, Futakuchi M, Lyssiotis CA, et al. A cross-species analysis of a mouse model of breast cancer-specific osteolysis and human bone metastases using gene expression profiling. BMC Cancer. 2011;11:304. doi:10.1186/1471-2407-11-30421774828
   PubMed Web of Science ®Google Scholar
• Giulietti M, Occhipinti G, Principato G, et al. Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development. Cell Oncol (Dordr). 2016;39(4):379–388. doi:10.1007/s13402-016-0283-727240826
   PubMed Web of Science ®Google Scholar
• Zhang X, Cai J, Zheng Z, et al. A novel ER-microtubule-binding protein, ERLIN2, stabilizes cyclin B1 and regulates cell cycle progression. Cell Discov. 2015;1:15024. doi:10.1038/celldisc.2015.2427462423
   PubMed Web of Science ®Google Scholar
• Wang G, Liu G, Wang X, et al. ERLIN2 promotes breast cancer cell survival by modulating endoplasmic reticulum stress pathways. BMC Cancer. 2012;12:225. doi:10.1186/1471-2407-12-22522681620
   PubMed Web of Science ®Google Scholar
• Wu H, Li J, Guo E, et al. MiR-410 acts as a tumor suppressor in estrogen receptor-positive breast cancer cells by directly targeting ERLIN2 via the ERS pathway. Cell Physiol Biochem. 2018;48(2):461–474. doi:10.1159/00049177730016800
   PubMedGoogle Scholar
• Li X, Wenes M, Romero P, et al. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol. 2019;16(7):425–441. doi:10.1038/s41571-019-0203-730914826
   PubMed Web of Science ®Google Scholar
• Elia I, Doglioni G, Fendt SM. Metabolic Hallmarks of metastasis formation. Trends Cell Biol. 2018;28(8):673–684. doi:10.1016/j.tcb.2018.04.00229747903
   PubMed Web of Science ®Google Scholar
• Botzer LE, Maman S, Sagi-Assif O, et al. Hexokinase 2 is a determinant of neuroblastoma metastasis. Br J Cancer. 2016;114(7):759–766. doi:10.1038/bjc.2016.2626986252
   PubMed Web of Science ®Google Scholar
• Sun H, Zhu A, Zhang L, et al. Knockdown of PKM2 suppresses tumor growth and invasion in lung adenocarcinoma. Int J Mol Sci. 2015;16(10):24574–24587. doi:10.3390/ijms16102457426501265
   PubMed Web of Science ®Google Scholar
• Bonuccelli G, Tsirigos A, Whitaker-Menezes D, et al. Ketones and lactate “fuel” tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle. 2010;9(17):3506–3514. doi:10.4161/cc.9.17.1273120818174
   PubMed Web of Science ®Google Scholar
• Lemberg KM, Vornov JJ, Rais R, et al. We’re not “DON” yet: optimal dosing and prodrug delivery of 6-Diazo-5-oxo-L-norleucine. Mol Cancer Ther. 2018;17(9):1824–1832. doi:10.1158/1535-7163.MCT-17-114830181331
   PubMed Web of Science ®Google Scholar
• Lynch G, Kemeny N, Casper E. Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma. Am J Clin Oncol. 1982;5(5):541–543. doi:10.1097/00000421-198210000-000147180833
   PubMed Web of Science ®Google Scholar
• Leone RD, Zhao L, Englert JM, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019;366:1013–1021. doi:10.1126/science.aav258831699883
   PubMed Web of Science ®Google Scholar
• McDonald G, Deepak S, Miguel L, et al. Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. J Clin Invest. 2014;124(2):712–724. doi:10.1172/JCI6957124463447
   PubMed Web of Science ®Google Scholar
• Bettencourt IA, Powell JD. Targeting metabolism as a novel therapeutic approach to autoimmunity, inflammation, and transplantation. J Immunol. 2017;198(3):999–1005. doi:10.4049/jimmunol.160131828115589
   PubMed Web of Science ®Google Scholar
• Payen VL, Porporato PE, Baselet B, et al. Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway. Cell Mol Life Sci. 2016;73(7):1333–1348. doi:10.1007/s00018-015-2098-526626411
   PubMed Web of Science ®Google Scholar
• Noorolyai S, Shajari N, Baghbani E, et al. The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019;698:120–128. doi:10.1016/j.gene.2019.02.07630849534
   PubMed Web of Science ®Google Scholar
• Sun C, Li X, Guo E, et al. MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis. Oncogene. 2019. doi:10.1038/s41388-019-1090-1
   Web of Science ®Google Scholar
• Sun F, Wang J, Sun Q, et al. Interleukin-8 promotes integrin beta3 upregulation and cell invasion through PI3K/Akt pathway in hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):449. doi:10.1186/s13046-019-1455-x31684995
   PubMed Web of Science ®Google Scholar